Patients with "Special" Cardiovascular Risk. Modern Aspects of the Need for Preventive Monitoring of Young People with Low Severity of Predictors of Cardiovascular Diseases
https://doi.org/10.31550/1727-2378-2023-22-8-33-39
Abstract
Aim. To review the literature on topical issues of possible complications of the use of androgenic anabolic steroids (AAS) from the cardiovascular system and the role of abuse of AAS in increasing individual cardiovascular risk.
Key points. The article reflects the historical stages of the application of AAS. The main pathophysiological mechanisms of the development of undesirable effects from the cardiovascular system have been established. Potential strategies for reducing the risk of side effects and complications from the circulatory system are proposed.
Conclusion. There is a trend of steadily increasing consumption of AAS in the absence of medical recommendations and control, which creates significant prerequisites for increasing cardiovascular risk in people engaged in recreational physical activity who do not fall into the field of preventive cardiology.
About the Authors
E. V. Kisilenko
S.M. Kirov Military Medical Academy
Russian Federation
Russian Federation
47 Zagorodny Prosp, St. Petersburg, 198013
A. D. Sobole
S.M. Kirov Military Medical Academy
Russian Federation
Russian Federation
47 Zagorodny Prosp, St. Petersburg, 198013
D. V. Cherkashin
S.M. Kirov Military Medical Academy
Russian Federation
Russian Federation
47 Zagorodny Prosp, St. Petersburg, 198013
References
1. Russian National Congress of Cardiologists Cardiology 2022: a new strategy in a new reality — openness, unity, sovereignty: September 29 – October 1, 2022, Kazan. Kazan; 2022. 787 p. (in Russian)
2. Kontsevaya A.V., Mukaneeva D.K., Myrzamatova A.O. et al. Economic damage of risk factors associated with morbidity and mortality from major chronic non-communicable diseases in Russia in 2016. Cardiovascular Therapy and Prevention. 2020;19(1):48–55. (in Russian). DOI: 10.15829/1728-8800-2020-1-2396
3. Freeman E.R., Bloom D.A., McGuire E.J. A brief history of testosterone. J. Urol. 2001;65(2):371–373. DOI: 10.1097/00005392-200102000-00004
4. Matfin G. The rejuvenation of testosterone: philosopher’s stone or Brown-Sequard Elixir? Ther. Adv. Endocrinol. Metab. 2010;1(4):151–154. DOI: https://doi.org/10.1177/2042018810385052
5. Lykhonosov M.P., Babenko A.V. Prevalence of anabolic androgenic steroid use, its eff ect on the male pituitarygonadal axis, and the possibility of reproductive rehabilitation. Problems of Endocrinology. 2019;65(2):124–133. (In Russian). DOI: https://doi.org/10.14341/probl9997
6. Seara F.A.C., Olivares E.L., Nascimento J.H.M. Anabolic steroid excess and myocardial infarction: from ischemia to reperfusion injury. Steroids. 2020;161:108660. DOI: 10.1016/j.steroids.2020.108660
7. Perry J.C., Schuetz T.M., Memon M.D. et al. Anabolic steroids and cardiovascular outcomes: the controversy. Cureus. 2020;12(7):e9333. DOI: 10.7759/cureus.9333
8. Goldman A.L., Pope Jr. H.G., Bhasin S. The health threat posed by the hidden epidemic of anabolic steroid use and body image disorders among young men. J. Clin. Endocrinol. Metab. 2019;104(4):1069–1074. DOI: 10.1210/jc.2018-01706
9. Serdyuk P.L. On the problem of combating doping in professional sports in Russia. Moscow; 2021. (in Russian)
10. Lykhonosov M.P., Babenko A.Yu. The medical aspect of using anabolic androgenic steroids in males attending gyms of Saint Petersburg. Problems of Endocrinology. 2019;65(1):19–30. (in Russian). DOI: https://doi.org/10.14341/probl9832
11. Usov E.G., Mammedov E.F., Samsonov V.A. On the validity of the criminalization of the identified turnover anabolic steroid. Bulletin of the Moscow University of the Ministry of Internal Affairs of Russia. 2022;(2):236–238. (in Russian). DOI: 10.24412/2073-0454-2022-2-236-238
12. Samieinasab M.R., Shahraki M.R., Samieinasab F., Najafi S. Influence of nandrolone decanoate administration on serum lipids and liver enzymes in rats. ARYA Atheroscler. 2015;11(4):256–260.
13. Achar S., Rostamian A., Narayan S.M. Cardiac and metabolic effecоjcard.2010.05.013
14. Souza F.R., Dos Santos M.R., Porello R.A. et al. Diminished cholesterol efflux mediated by HDL and coronary artery disease in young male anabolic androgenic steroid users. Atherosclerosis. 2019;283:100–105. DOI: 10.1016/j.atherosclerosis.2019.02.006
15. Gonçalves R.V., Santos J.D.B., Silva N.S. et al. Trans-fatty acids aggravate anabolic steroid-induced metabolic disturbances and differential gene expression in muscle, pancreas and adipose tissue. Life Sci. 2019;232:116603. DOI: 10.1016/j.lfs.2019.116603
16. de Andrade T.U., Haguihara S.C.G.C., Falsoni R.M.P. et al. Stanozolol promotes lipid deposition in the aorta through an imbalance in inflammatory cytokines and oxidative status in LDLr knockout mice fed a normal diet. Basic Clin. Pharmacol. Toxicol. 2019;124(4):360–369. DOI: 10.1111/bcpt.13143
17. Niedfeldt M.W. Anabolic steroid effect on the liver. Curr. Sports Med. Rep. 2018;17(3):97–102. DOI: 10.1249/JSR.0000000000000467
18. Zhu D., Hadoke P.W., Wu J. et al. Ablation of the androgen receptor from vascular smooth muscle cells demonstrates a role for testosterone in vascular calcification. Sci. Rep. 2016;6:24807. DOI: 10.1038/srep24807
19. Rosca A.E., Stancu C.S., Badiu C. et al. Lipid profile changes induced by chronic administration of anabolic androgenic steroids and taurine in rats. Medicina (Kaunas). 2019;55(9):540. DOI: 10.3390/medicina55090540
20. Mogharnasi M., Cheragh-Birjandi K., Cheragh-Birjandi S., Taher-iChadorneshin H. The effects of resistance and endurance training on risk factors of vascular inflammation and atherogenesis in non-athlete men. Interv. Med. Appl. Sci. 2017;9:185–190. DOI: https://doi.org/10.1556/1646.9.2017.36
21. Carson P., Hong C.J., Otero-Vinas M. et al. Liver enzymes and lipid levels in patients with lipodermatosclerosis and venous ulcers treated with a prototypic anabolic steroid (stanozolol): a prospective, randomized, double-blinded, placebo-controlled trial. Int. J. Low Extrem. Wounds 2015;14:11–18. DOI: https://doi.org/10.1177/1534734614562276
22. Peoples K., Kobe D., Campana C., Simon E. Hyperhomocysteinemiainduced myocardial infarction in a young male using anabolic steroids. Am. J. Emerg. Med. 2014;32:941–948. DOI: https://doi.org/10.1016/j.ajem.2014.01.041
23. Riezzo I., De Carlo D., Neri M. et al. Heart disease induced by AAS abuse, using experimental mice/rats models and the role of exercise-induced cardiotoxicity. Mini Rev. Med. Chem 2011;11:409–424. DOI: 10.2174/138955711795445862
24. Lippi G., Banfi G. Doping and thrombosis in sports. Semin. Thromb. Hemost. 2011;37:918–928. DOI: 10.1055/s-0031-1297371
25. Frati P., Busardo F.P., Cipolloni L. et al. Anabolic androgenic steroid (AAS) related deaths: autoptic, histopathological and toxicological findings. Curr. Neuropharmacol. 2015;13:146–159. DOI: 10.2174/1570159X13666141210225414
26. Shamloul R.M., Aborayah A.F., Hashad A., Abd-Allah F. Anabolic steroids abuse-induced cardiomyopathy and ischaemic stroke in a young male patient. BMJ Case Rep. 2014;2014:bcr2013203033. DOI: 10.1136/bcr-2013-203033
27. Chang S., Rasmussen J.J., Frandsen M.N. et al. Procoagulant state in current and former anabolic androgenic steroid abusers. Thromb. Haemost. 2018;118:647–653. DOI: 10.1055/s-0038-1636540
28. Achar S., Rostamian A., Narayan S.M. Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. Am. J. Cardiol. 2010;106:893–901. DOI: 10.1016/j.amjcard.2010.05.013
29. Dhar R., Stout C.W., Link M.S. et al. Cardiovascular toxicities of performanceenhancing substances in sports. Mayo Clin. Proc. 2005;80:1307–1315. DOI: 10.4065/80.10.1307
30. Sabzi F., Faraji R. Large in-transient left ventricular thrombus due to anabolic steroid-induced cardiomyopathy. Ind. J. Crit. Care Med. 2017;21(1):51. DOI: 10.4103/0972-5229.198328
31. Colburn S., Childers W.K., Chacon A. et al. The cost of seeking an edge: recurrent renal infarction in setting of recreational use of anabolic steroids. Ann. Med. Surg. (Lond.). 2017;14:25–28. DOI: 10.1016/j.amsu.2017.01.015
32. Lemiński A., Kubis M., Kaczmarek K. et al. When bodybuilding goes wrongbilateral renal artery thrombosis in a long-term misuser of anabolic steroids treated with AngioJet rheolytic thrombectomy. Int. J. Environ. Res. Public Health. 2022;19(4):2122. DOI: 10.3390/ijerph19042122
33. Tashiro K., Iso Y., Tsujiuchi M. et al. Subacute stent thrombosis after primary percutaneous coronary intervention in a middle-aged anabolic steroidabusing bodybuilder. JACC Case Rep. 2020;3(4):537–541. DOI: 10.1016/j.jaccas.2020.09.038
34. Christou G.A., Christou K.A., Nikas D.N., Goudevenos J.A. Acute myocardial infarction in a young bodybuilder taking anabolic androgenic steroids: a case report and critical review of the literature. Eur. J. Prev. Cardiol. 2016;23(16):1785–1796. DOI: 10.1177/2047487316651341
35. Hernández-Guerra A.I., Tapia J., Menéndez-Quintanal L.M., Lucena J.S. Sudden cardiac death in anabolic androgenic steroids abuse: case report and literature review. Forensic Sci. Res. 2019;4(3):267–273. DOI: 10.1080/20961790.2019.1595350
36. Sonmez E., Turkdogan K.A., Yilmaz C. et al. Chronic anabolic androgenic steroid usage associated with acute coronary syndrome in bodybuilder. Turk. J. Emerg. Med. 2016;16:35–37. DOI: 10.1016/j.tjem.2014.11.001
37. Ferrer M., Encabo A., Marin J., Balfagon G. Chronic treatment with the anabolic steroid, nandrolone, inhibits vasodilator responses in rabbit aorta. Eur. J. Pharmacol. 1994;252:233–241. DOI: 10.1016/0014-2999(94)90602-5
38. Liu K., Shen C., Chen X. Expression of androgen receptor in coronary artery in the cases of sudden coronary death. Int. J. Clin. Exp. Pathol 2015;8: 3742–3747.
39. Rasmussen J.J., Schou M., Madsen P.L. et al. Increased blood pressure and aortic stiffness among abusers of anabolic androgenic steroids: potential effect of suppressed natriuretic peptides in plasma? J. Hypertens. 2018;36:277–285. DOI: 10.1097/HJH.0000000000001546
40. D’Andrea A., Caso P., Salerno G. et al. Left ventricular early myocardial dysfunction after chronic misuse of anabolic androgenic steroids: a Doppler myocardial and strain imaging analysis. Br. J. Sports Med. 2007;41:149–155. DOI: 10.1136/bjsm.2006.030171
41. Lenders J.W., Demacker P.N., Vos J.A. et al. Deleterious effects of anabolic steroids on serum lipoproteins, blood pressure, and liver function in amateur body builders. Int. J. Sports Med. 1988;9:19–23. DOI: 10.1055/s-2007-1024972
42. Junior J.F.C.R., Silva A.S., Cardoso G.A. et al. Androgenic-anabolic steroids inhibited post-exercise hypotension: a case control study. Braz. J. Phys. Ther. 2018;22(1):77–81. DOI: 10.1016/j.bjpt.2017.07.001
43. Roşca A.E., Stoian I., Badiu C. et al. Impact of chronic administration of anabolic androgenic steroids and taurine on blood pressure in rats. Braz. J. Med. Biol. Res. 2016;49(6):e5116. DOI: 10.1590/1414-431X20165116
44. Ferrera P.C., Putnam D.L., Verdile V.P. Anabolic steroid use as the possible precipitant of dilated cardiomyopathy. Cardiology. 1997;88:218–220. DOI: 10.1159/000177333
45. Nieminen M.S., Ramo M.P., Viitasalo M. et al. Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Eur. Heart J. 1996;17:1576–1583. DOI: 10.1093/oxfordjournals.eurheartj.a014724
46. Milevski S.V., Sawyer M., La Gerche A., Paratz E. Anabolic steroid misuse is an important reversible cause of cardiomyopathy: a case report. Eur. Heart J. Case Rep. 2022;6(7):ytac271. DOI: 10.1093/ehjcr/ytac271
47. Li C., Adhikari B.K., Gao L. et al. Performance-enhancing drugs abuse caused cardiomyopathy and acute hepatic injury in a young bodybuilder. Am. J. Mens Health. 2018;12(5):1700–1704. DOI: 10.1177/1557988318783504
48. Cecchi R., Muciaccia B., Ciallella C. et al. Ventricular androgenic-anabolic steroid-related remodeling: an immunohistochemical study. Int. J. Legal Med. 2017;131(6):1589–1595. DOI: 10.1007/s00414-017-1589-3
49. Fanton L., Belhani D., Vaillant F. et al. Heart lesions associated with anabolic steroid abuse: comparison of post-mortem findings in athletes and norethandrolone-induced lesions in rabbits. Exp. Toxicol. Pathol. 2009;61(4):317–323. DOI: 10.1016/j.etp.2008.09.007
Review
For citations:
Kisilenko E.V., Sobole A.D., Cherkashin D.V. Patients with "Special" Cardiovascular Risk. Modern Aspects of the Need for Preventive Monitoring of Young People with Low Severity of Predictors of Cardiovascular Diseases. Title. 2023;22(8):33-39. (In Russ.) https://doi.org/10.31550/1727-2378-2023-22-8-33-39
Views:
13
Email this article 